Welcome to our dedicated page for American Well SEC filings (Ticker: AMWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Telehealth revenue models, multi-year platform investments, and value-based care contracts make American Well Corporation’s disclosures dense reading. If you have ever searched “American Well SEC filings explained simply” or wondered how board decisions affect the hybrid-care roadmap, you know that a single footnote in the 10-K can change your valuation thesis. Add insider moves and sudden 8-K announcements and the research pile grows quickly.
Our SEC Filings hub removes that friction. The moment EDGAR posts a new document—whether it is an “American Well quarterly earnings report 10-Q filing” or an “American Well 8-K material events explained”—our system flags it, then feeds it to Stock Titan’s AI engine. You receive concise overviews, key metric extractions, and contextual links, so “understanding American Well SEC documents with AI” takes minutes, not late nights. Need to monitor “American Well insider trading Form 4 transactions”? We stream “American Well Form 4 insider transactions real-time” and highlight option grants, automatic sales, and beneficial-owner changes in plain language.
Investors use this page to drill into specifics that drive telehealth economics. The “American Well annual report 10-K simplified” section outlines segment revenue for virtual primary care, platform licensing, and professional services. Each “American Well earnings report filing analysis” tracks visit volumes, payer mix, and margin trends across the care continuum. A dedicated tab surfaces “American Well proxy statement executive compensation” so you can compare stock awards to clinical-outcome targets. Practical use cases include spotting “American Well executive stock transactions Form 4” before earnings calls, mapping deferred revenue shifts across quarters, and following R&D spend tied to strategic partnerships. All filings stay in one place, updated in real time, with AI-powered summaries, expert notes, and full original PDFs ready for deep dives.
American Well Corp reported an insider transaction by its President, International. On December 1, 2025, the reporting person sold 3,574 shares of Class A common stock at a price of $4.0573 per share. The filing explains that these sales were made solely to pay taxes arising from the vesting and settlement of restricted stock units on the same date through an automatic “sell to cover” transaction, rather than a discretionary trade.
After this transaction, the reporting person beneficially owns 123,577 Class A shares directly and 114,250 Class A shares indirectly through her husband. This reflects ongoing equity ownership in American Well while handling the tax impact of stock-based compensation.
American Well Corporation insider Phyllis Gotlib has filed a notice to sell 3,574 shares of Class A common stock through Morgan Stanley on the NYSE, with an aggregate market value of 14,501. The company reports 14,723,951 Class A shares outstanding, so this is a small transaction relative to the total.
The shares to be sold are tied to a restricted stock unit grant, with 6,786 Class A shares vesting on 12/01/2025 and paid via that vesting. Over the prior three months, Gotlib sold 4,781 and 4,959 Class A shares on 09/02/2025 and 10/01/2025, generating gross proceeds of 32,422.35 and 30,281.64. By signing the notice, the seller represents that she is not aware of any undisclosed material adverse information about American Well’s operations.
Caledonia (Private) Investments Pty Limited and Caledonia US, LP filed Amendment No. 4 to Schedule 13G reporting their beneficial ownership in American Well Corp (AMWL).
The filing lists 640,000 shares of Class A common stock with 4.35% of the class, all with shared voting and dispositive power and no sole power. Item 5 indicates “Ownership of 5 percent or less of a class.” The date of the event requiring the filing is 09/30/2025, and the certification states the securities are held in the ordinary course and not to change or influence control.
American Well (AMWL) reported third‑quarter results for the period ended September 30, 2025. Revenue was $56.3 million, down from $61.0 million a year ago, as visit volumes declined while higher‑margin platform subscriptions grew. Loss from operations narrowed to $29.3 million from $47.4 million, reflecting lower costs across R&D, sales and marketing, and cost of revenue.
Platform subscription revenue rose to $30.9 million from $26.2 million, while visit revenue fell to $21.2 million from $27.5 million. Net loss attributable to the company improved to $32.4 million from $43.5 million; basic and diluted net loss per share was $2.00 versus $2.87. Cash, cash equivalents and restricted cash were $201.7 million as of September 30, 2025, compared with $245.4 million a year earlier. Operating cash use for the nine months was $48.6 million, an improvement from $113.9 million.
Year‑to‑date, the company recognized an $8.7 million gain from the January divestiture of its telepsychiatry APC Business. AMWL and Cleveland Clinic agreed to liquidate their CCAW joint venture, with remaining transition activities running through March 31, 2026. Deferred revenue ended at $32.0 million, down from $56.0 million as of December 31, 2024.
American Well Corporation (Amwell) reported that it announced financial results for the fiscal quarter ended September 30, 2025. The company furnished its Earnings Report as Exhibit 99.1.
Amwell will host a conference call to discuss results today at 5 p.m. ET, accessible via live webcast at the provided link. A replay will be available for approximately 90 days at investors.amwell.com. The furnished materials are not deemed “filed” under Section 18 of the Exchange Act.
Paul McNeice, Chief Accounting Officer of American Well Corp (AMWL), reported a sale of 332 shares of Class A common stock on 10/01/2025 at a price of $6.1064 per share. The filing states the sale was an automatic sell-to-cover to satisfy the tax liability from the vesting and settlement of restricted stock units that occurred the same day. After the transaction, the reporting person beneficially owned 3,560 shares. The Form 4 was signed on behalf of Mr. McNeice by an attorney-in-fact on 10/03/2025.
American Well Corp (AMWL) reported an insider transaction by its President, International, Phyllis Gotlib. On October 1, 2025, she sold 4,959 shares of Class A Common Stock at $6.1064 per share. According to the note, the sale was an automatic “sell-to-cover” to satisfy tax liabilities from the vesting and settlement of restricted stock units, and did not represent a discretionary trade.
After the transaction, her beneficial ownership was 127,151 shares held directly and 114,250 shares held indirectly by her husband.
American Well Corp (AMWL) notice of proposed securities sale under Rule 144. The filing states an intended sale of 4,959 shares of Class A common stock through Morgan Stanley on the NYSE with an aggregate market value of $30,281.64. The filer reports holding 14,162,309 shares outstanding.
The shares were acquired upon vesting of a restricted stock unit grant from American Well Corporation, showing 7,032 RSUs vested on the acquisition date. The filing also discloses two prior sales by the same account in the past three months: 4,958 shares (gross proceeds $42,773.16) and 4,781 shares (gross proceeds $32,422.35).
Deborah C. Jackson, a director of American Well Corp (AMWL), reported a sale of 4,531 shares of Class A common stock on 09/15/2025 at an average price of $6.5647 per share, leaving her with 39,132 shares beneficially owned directly and 612 shares indirectly held by her spouse.
The filing states the sale was executed under a Rule 10b5-1 trading plan adopted May 20, 2025, and the shares were sold to cover tax liabilities from the vesting and settlement of restricted stock units on June 10, 2025. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Jackson on 09/17/2025.
Dmitry Zamansky, Chief Product & Technology Officer of American Well Corporation (AMWL), reported a sale of 25,605 shares of Class A common stock on 09/03/2025 at a price of $6.7724 per share. After the transaction, he beneficially owned 197,711 shares. The Form 4 states the sale was a non-discretionary "sell to cover" to pay tax liabilities arising from the vesting and settlement of restricted stock units on the same date. The filing is signed by an attorney-in-fact on behalf of Mr. Zamansky on 09/04/2025. The disclosure indicates routine insider tax-related selling rather than a voluntary open-market trade by the reporting person.
FAQ
What is the current stock price of American Well (AMWL)?
What is the market cap of American Well (AMWL)?
